MS Minute: Ibudilast
Ibudilast is a phosphodiesterase inhibitor that has shown some benefit for progressive multiple sclerosis in a phase 2 trial.
Abdul R. Alchaki, MD; and Andrew D. Goodman, MD
A triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss.
Ilka Kleffner, MD; Catharina C. Gross, PhD; Marius Ringelstein, MD; Jörg Rehrmann, MD; Markus Kraemer, MD; and Jan Dörr, MD
Challenge Case Report: Aseptic Meningitis Worsening With Treatment
Diagnosis should be re-evaluated when clinical situations change.
David Horvat, MD; Jack Lovell, DO; and Glen Cook Jr, MD
Case Report: Seizure, Fever, Hallucinations, & Vision Loss
A circuitous route to dual diagnoses.
Elizabeth Carroll, MD; Asya I. Wallach, MD; Arielle Kurzweil, MD; Steven Frucht, MD; Thomas Berk, MD; Michael Boffa, MD; and Ilya Kister, MD
MS Minute: Oral Therapies for MS
The advent of oral therapies has ushered in a new phase of disease-modifying treatments.
Neeta Garg, MD; Micheline McCarthy, MD, PhD; and Ameeta Karmarkar, MD
Case Report: Hemiparkinsonism in a Patient With Multiple Sclerosis
In this case, there was a causal relationship between comorbid diseases.
Andrea P. Lee, MD; Giulietta M. Riboldi, MD; Ilya Kister, MD; Jonathan E. Howard, MD; and Ritesh A. Ramdhani, MD
Dizziness and Vertigo
Part 1: Untangling the complexity of dizziness and vertigo requires a careful history.
Daniel R. Gold, DO; and Ari A. Shemesh, MD
Guest Medical Editor's Page
The Importance of Sleep
Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
Logan Schneider, MD
Multiple Sclerosis Minute: Telemedicine and Multiple Sclerosis
Telemedicine is acceptable to patients and clinicians in the continuum of clinic-to-in-home care and reduces barriers to care.
Valerie J. Block, DPTSc, PT; and Riley Bove, MD, MMSc
Emerging Therapies for Progressive Multiple Sclerosis
A number of agents with putative neuroprotective effects have shown promise in recent clinical trials.
Matthew Tremblay, MD, PhD
Pediatric-Onset Multiple Sclerosis
Information from clinical trials in children with MS is furthering understanding and improving treatment options for this rare presentation.
Brenda L. Banwell, MD; and Duriel I. Hardy, MD
Immunopathogenesis of Multiple Sclerosis
Disruption of immune tolerance, inflammation, and blood-brain–barrier breach lead to demyelination and axonal injury.
Neeta Garg, MD; Ye Hu, MD; and Kottil W. Rammohan, MD
Neuromyelitis Optica Spectrum Disorders
It is critical to maintain a high index of suspicion for these conditions when evaluating a patient with demyelination to avoid delays in treatment.
Michael J. Bradshaw, MD; and Dorlan Kimbrough, MD
POINT-COUNTERPOINT: Natalizumab Extended-Interval Dosing
Optimism vs caution for using extended-interval dosing to prevent progressive multifocal leukoencephalopathy.
David B. Clifford, MD; and John F. Foley, MD
Cover Focus: Multiple Sclerosis & Demyelinating Disorders
Multiple Sclerosis Misdiagnosis
Accurate diagnosis requires correspondence to typical clinical syndromes, correct interpretation of radiologic and CSF data, and thorough evaluation for mimics.
Alexandra Galati, MD; and Marwa Kaisey, MD
Physical therapy, exercise, physical activity, and medications adapted to individual needs can all help maintain the ability to walk.
Michelle H. Cameron, MD, PT, MCR; and Ylva E. Nilsagård, PT, PhD
Guest Medical Editor's Page
A Coming of Age for Neuroimmunology
Increasingly complex diagnostics and highly effective disease-modifying therapy come with challenges in clinical decision making.
Aaron M. Carlson, MD
Case Report: Longitudinally Extensive Transverse Myelitis
The borderline of neuromyelitis optica and systemic lupus erythematosus.
Ylec Mariana Cardenas, MD; Lakshmi Leishangthem, MD; Aparna Prabhu, MD; David Roby, MD; Pooja SirDeshpande, MD; and Saman Zafar, MD